Dragonfly Biosciences’s CBD oil products are now available on prescription under the Therapeutic Goods Administration’s Special Access Scheme.
Dragonfly’s CBD oil and topical products are sold over the counter and online in the UK, US and Europe and Australian patients can now access its narrow spectrum 1,000mg and 3,000mg CBD oil on prescription.
The company is seeking further approval for Dragonfly CBD to be listed on the Australian Register of Therapeutic Goods and hopes to make it available over the counter in the next 12 to 18 months.
It has a distribution agreement with Health House International in Australia which it said has the capacity to scale up to meet increasing demand.
Chief executive Regan Saveall said: “We control the entire production process from seed to shelf so we can ensure the quality of Dragonfly’s products and give consumers confidence they contain the stated amount of CBD; are THC-free; will have a batch number and use-by date on every pack and are compliant with all regulatory frameworks.”